Objective:Matrix metalloproteinases (MMPs) play an important role in modeling and remodeling the extracellular matrix in leiomyomas. Hence, we investigated whether associations exist between leiomyomas and promoter polymorphisms in the MMP-1 and MMP-9 genes in a Japanese population.
Methods:We compared the distribution of polymorphisms in the promoter regions of MMP-1 (- 1607 1G/2G) and MMP-9 (- 1562 C/T) in 267 leiomyoma patients and 184 control patients using polymerase chain reaction-fragment-length polymorphism (PCR-RELP) analysis.
Results:The allele frequencies of the MMP-1 - 1607 2G and MMP-9 - 1562 T polymorphisms were 74.6% and 18.6% in leiomyoma patients, and 71.3% and 18.6% in control patients, respectively. No significant differences in allele frequencies or genotype distributions were found between leiomyoma and control patients. Moreover, no associations were found between MMP-1 and MMP-9 genotypes and leimoyoma size or a family history of the condition.
Conclusion:These findings suggest that MMP-1 and MMP-9 promoter polymorphisms are unlikely to be associated with an increased risk of uterine leiomyoms in Japanese women.
1. Ding L, Xu J, Luo X, et al. Gonadotropin releasing hormone and transforming growth factor beta activate mitogen-activated protein kinase/extracellularly regulated kinase and differentially regulate fibronectin, type I collagen, and plasminogen activator nihibitor-1 expression in leiomyoma and myometrial smooth muscle cells. J Clin Endocrinol Metab2004;89:5549-5557.
2.
2. McCawley LJ, Matrisian LM. Matrix metalloproteinases: Multifunctional contributors to tumor progression. Mol Med Today2000;6:149-156.
3.
3. Vu TH, Werb Z. Matrix metalloproteinases: Effectors of development and normal physiology. Genes Dev2000;14:2123-2133.
4.
4. Bodner-Adler B, Bodner K, Kimberger O, et al. Expression of matrix metalloproteinases in patients with uterine smooth muscle tumors: An immunohistochemical analysis of MMP-1 and MMP-2 protein expression in leiomyoma, uterine smooth muscle tumor of uncertain malignant potential, and leiomyosarcoma. J Soc Gynecol Investig2004;11:182-186.
5.
5. Inagaki N, Ung L, Otani T, et al. Uterine cavity matrix metalloproteinases and cytokines in patients with leiomyoma, adanomyosis or endometrial polyp. Eur J Obstet Gynecol Reprod Biol2003;111:197-203.
6.
6. Hinoda Y, Okayama N, Takano N, et al. Association of functional polymorphisms of matrix metalloproteinase (MMP)-1 and MMP-3 genes with colorectal cancer. Int J Cancer2002;102:526-529.
7.
7. Nishioka Y, Kobayashi, Sagae S, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter in endometrial carcinomas. Jpn J Cancer Res2000;91:612-615.
8.
8. Przybylowska K, Zielinska J, Zadrozny M, et al. An association between the matrix metalloprotinase-1 promoter gene polymorphism and lymphnode metastasis in breast cancer. J Exp Clin Cancer Res2004;23:121-125.
9.
9. Zhu Y, Spitz MR, Lei L, et al. A single nucleotide polymorphism in the matrix metalloprotinase-1 promoter enhances lung cancer susceptibility. Cancer Res2001;61:7825-7829.
10.
10. Matsumura S, Oue Nk, Kitadai Y, et al. A single nucleotide polymorphism in the MMP-1 promoter is correlated with histological differentiation of gastric cancer. J Cancer Res Clin Oncol2004;130:259-265.
11.
11. Minematsu N, Nakamura H, Tateno H, et al. Genetic polymorphism in matrix metalloprotinase-9 and pulmonary emphysema. Biochem Biophys Res Commun2001;289:116-119.
12.
12. Nojiri T, Morita H, Imai, Y et al. Genetic variations of matrix metalloproteinase-1 and -3 promoter regiosn and their associations with susceptibility to myocardial infarction in Japanese. Int J Cardiol2003;92:181-186.
13.
13. Yamada Y, Ando F, Niino N, et al. Association of a polymorphism of the matrix metallproteinase-9 gene with bone mineral density in Japanese men. Metabolism2004;53:135-137.
14.
14. McCawley LJ, Matrisian LM. Matrix metalloproteinases: They're not just for matrix any more!Curr Opin Cell Biol2001;13:534-540.
15.
15. Zhang B, Ye S, Hermann SM, et al. Functional polymorphism in the regulatory region of gelatinase B gene in relation to severity of coronary atherosclerosis. Circulation1999;99:1788-1794.
16.
16. Whitelock JM, Murdoch AD, Iozzo RV, et al. The degradation of human endothelial cell-derived perlecan and release of bound basic fibroblast growth factor by stromelysin, collagenase, plasmin, and heparanases. J Biol Chem1996;271:10079-10086.
17.
17. Yu Q, Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 protecolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev2000;14:163-176.
18.
18. Stewart EA, Friedman AJ, Peck N, et al. Relative overexpression of colalgen type I and collagen type III messenger ribonucleic acids by uterine leiomyomas during the proliferative phase of the menstrual cycle. J Clin Endocrinol Metab1994;79:900-906.
19.
19. Rutter JL, Mitchell TI, Buttice G, et al. A single nucleotide polymorphism in the matrix metalloproteinase-1 promoter creates an Ets binding site and augments transcription. Cancer Res1998;58:5321-5325.
20.
20. Zhang B, Henney A, Eriksson P, et al. Genetic variation at the matrix metalloproteinase-9 locus on chromosome 20q12.2-13.1. Hum Genet1999;105:418-423.
21.
21. Blankenberg S, Rupprecht HJ, Poirier O, et al. Plasma concentrations and genetic variation of matrix metalloproteinase 9 and prognosis of patients with cardiovascular disease. Circulation2003;107:1579-1585.
22.
22. Medley TL, Cole TJ, Dart AM, et al. Matrix metalloprotinase-9 genotype influences large artery stiffness through effects on aortic gene and protein expressions. Arteriosclr Thromb Vasc Biol2004;24:1479-1484.
